PsychedelicNewsBreaks

TuesdayJul 14, 2020 11:23 am

PsychedelicNewsBreaks – Why Cybin Corp. Is ‘One to Watch’

Cybin Corp. is Canada's premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi. A recent article discussing the company reads, “In particular, Cybin aims to further build upon and expand its intellectual property (‘IP’) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.” To view the full article, visit http://ibn.fm/7l5CK About Cybin Cybin is a…

Continue Reading

MondayJul 13, 2020 10:10 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Corporate Update

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today issued a corporate update. Among other items highlighted in the update, the Company continues to work with the British Columbia Securities Commission (the “Commission”) to complete its continuous disclosure review. Champignon Brands will continue to fully cooperate with the Commission to assist in completion of the review in a timely fashion. In addition, the Company’s board of directors, in June 2020, considered options for realizing additional value for the consumer-packaged goods (“CPG”) pillar of its business and contemplated a reorganization that would result in the spinout of this business into a…

Continue Reading

ThursdayJul 09, 2020 12:18 pm

PsychedelicNewsBreaks – MagicMed Industries Inc. Announces First Psychedelic Derivative Patent Filing in Anticipated Series

MagicMed Industries today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering composition of matter, drug formulation and process of preparation claims for novel psilocybin derivatives. According to the update, the patent filing is anticipated to be the first in a series of applications that together will protect the Company's broad portfolio of novel psilocybin molecular derivatives, the “PsybraryTM.” "We are excited by the new opportunities to partner with pharmaceutical manufacturers afforded by the library of derivatives that this patent application claims," MagicMed CEO and President, Dr. Joseph Tucker, stated…

Continue Reading

TuesdayJul 07, 2020 1:33 pm

PsychedelicNewsBreaks – Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film

Cybin Corp., Canada's premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, today announced its entry into a feasibility agreement with IntelGenx Corp. (OTCQB: IGXT) (TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals. “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen, stated in the news release. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver,…

Continue Reading

WednesdayJul 01, 2020 1:10 pm

PsychedelicNewsBreaks – Cybin Corp. Announces Reverse Take-Over and Up-To $21M Concurrent Private Placement

Cybin Corp., a mushroom life sciences company focused on psychedelic medicines and nutraceutical products, on Monday announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin. According to the update, completion of the transactions contemplated in the agreement will result in the reverse takeover of Clarmin by Cybin (the “Proposed Transaction”). In connection with the Proposed Transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (“Stifel GMP”)…

Continue Reading

MondayJun 29, 2020 1:27 pm

PsychedelicNewsBreaks – Mushrooms Take the Stage in First-Ever PsyTech Summit

The new era of mushrooms was featured in a recent Forbes article by Sara Brittany Somerset titled, “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health.” The article, which discusses psychedelics taking the stage in consumption and investing, reads, “PsychedeliTech, a ground-breaking new conference, incubator and discovery platform for psychedelic medicine will host Rick Doblin, Ph.D., founder and executive director of the Multidisciplinary Association for Psychedelic Studies (“MAPS”) as the keynote speaker at the first-ever PsyTech Summit, a forum for psychedelic science, innovation and investment conference, in Israel.” To view the full article, visit http://ibn.fm/tivNo…

Continue Reading

MondayJun 22, 2020 11:46 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Regulatory Review

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to Champignon’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company. “With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention.  Ensuring fulsome and timely disclosure…

Continue Reading

FridayJun 19, 2020 2:12 pm

PsychedelicNewsBreaks – Why Pure Extracts Corp. Is ‘One to Watch’

Headquartered in Pemberton, British Columbia, Pure Extracts is a private, plant-based extraction company with a new vertical in functional mushrooms. A recent article discussing the company reads, “Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bipolar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD, and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021. . . . Pure Extracts is well…

Continue Reading

FridayJun 19, 2020 10:19 am

PsychedelicNewsBreaks – Champignon Brands Inc.’s (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Dr. McIntyre / CRTCE Published in Two Peer Reviewed Study Journals

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (“MDD”) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company today announced that its Chief Executive Officer, Dr. Roger McIntyre, and the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) have been recently published in two peer reviewed study journals (the “Peer Reviewed Studies”) focusing on ketamine’s safety, tolerability and effectiveness. “The publications of data as it relates…

Continue Reading

WednesdayJun 17, 2020 1:25 pm

PsychedelicNewsBreaks – Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) Announces Phase 2 Clinical Trial of LSD to Treat Cluster Headaches Begins Treating Patients

Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), a leading neuro-pharmaceutical company focused on psychedelic inspired medicines, recently announced that the Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel's Liechti Lab has started treating patients. MindMed previously established an ongoing R&D collaboration with the University Hospital Basel's Liechti Lab to evaluate various therapeutic uses of psychedelics and next-gen psychedelic therapies. The double-blind, randomized, placebo-controlled two-phase cross-over study is examining the effects of an oral LSD pulse regimen in 30 patients with cluster headaches. “As we continue on our mission to discover, develop and…

Continue Reading